trans-1-(4-fluorophenyl)-3-(4-(4-methoxyphenyl)-2-oxo-1-(pyridin-2-ylmethyl)piperidin-3-yl)urea

ID: ALA5276203

Chembl Id: CHEMBL5276203

Max Phase: Preclinical

Molecular Formula: C25H25FN4O3

Molecular Weight: 448.50

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc([C@H]2CCN(Cc3ccccn3)C(=O)[C@@H]2NC(=O)Nc2ccc(F)cc2)cc1

Standard InChI:  InChI=1S/C25H25FN4O3/c1-33-21-11-5-17(6-12-21)22-13-15-30(16-20-4-2-3-14-27-20)24(31)23(22)29-25(32)28-19-9-7-18(26)8-10-19/h2-12,14,22-23H,13,15-16H2,1H3,(H2,28,29,32)/t22-,23-/m1/s1

Standard InChI Key:  JEWGZKROTZDNFF-DHIUTWEWSA-N

Alternative Forms

  1. Parent:

    ALA5276203

    ---

Associated Targets(Human)

FPR1 Tchem Formyl peptide receptor 1 (1372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FPR2 Tchem Lipoxin A4 receptor (3472 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 448.50Molecular Weight (Monoisotopic): 448.1911AlogP: 3.94#Rotatable Bonds: 6
Polar Surface Area: 83.56Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 13.79CX Basic pKa: 4.14CX LogP: 2.91CX LogD: 2.91
Aromatic Rings: 3Heavy Atoms: 33QED Weighted: 0.60Np Likeness Score: -1.37

References

1. Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM..  (2021)  Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.,  213  [PMID:33486199] [10.1016/j.ejmech.2021.113167]

Source